Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Semaglutide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    95 result(s) found for: Semaglutide. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2019-004594-44 Sponsor Protocol Number: NN9931-4553 Start Date*: 2021-06-28
    Sponsor Name:Novo Nordisk A/S
    Full Title: The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis
    Medical condition: Non-alcoholic steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DE (Ongoing) IE (Ongoing) CZ (Trial now transitioned) GR (Ongoing) DK (Trial now transitioned) FR (Ongoing) NL (Ongoing) SK (Trial now transitioned) PT (Trial now transitioned) BE (Ongoing) BG (Ongoing) PL (Ongoing) IT (Ongoing) HR (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003473-34 Sponsor Protocol Number: NN9536-4376 Start Date*: 2018-05-03
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity who have reached target dose during run-in period
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) PT (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-003275-42 Sponsor Protocol Number: MEC-2021-0478 Start Date*: 2023-04-13
    Sponsor Name:
    Full Title: The influence of different DIets on ALECTinib pharmacokinetics in NSCLC patients; the DIALECT study.
    Medical condition: Weight gain is a common side effect of alectinib therapy. Semaglutide could be used as medical anti-obesity drug to prevent alectinib-induced weight gain. Since semaglutide delays gastric emptying,...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002939-29 Sponsor Protocol Number: NN9536-4734 Start Date*: 2021-07-05
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of subcutaneous semaglutide 2.4 mg once-weekly in subjects with obesity and prediabetes
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004170-22 Sponsor Protocol Number: EX9536-4773 Start Date*: 2021-06-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of Semaglutide 2.4 mg once-weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction, and type 2 diabetes
    Medical condition: Heart failure with preserved ejection fraction Diabetes Mellitus, type 2
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) HU (Completed) SE (Completed) PL (Completed) AT (Completed) IT (Ongoing) ES (Ongoing) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004452-11 Sponsor Protocol Number: EX9536-4665 Start Date*: 2021-02-04
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of semaglutide 2.4 mg once weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction
    Medical condition: Heart failure with preserved ejection fraction Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) NL (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003654-83 Sponsor Protocol Number: INS-4603 Start Date*: 2019-10-23
    Sponsor Name:Novo Nordisk A/S
    Full Title: A TRIAL TO COMPARE THE INJECTION SITE PAIN EXPERIENCE OF 0.25 MG SEMAGLUTIDE B AND SEMAGLUTIDE D ADMINISTERED SC
    Medical condition: Healthy volunteers (Diabetes Mellitus, Type 2) (Overweight) (Obesity)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    20.0 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002590-22 Sponsor Protocol Number: NN9924-4338 Start Date*: 2019-07-25
    Sponsor Name:Novo Nordisk A/S
    Full Title: China multi-regional clinical trial: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-003436-36 Sponsor Protocol Number: NN9536-4373 Start Date*: 2018-05-17
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FI (Completed) DK (Completed) BG (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004848-29 Sponsor Protocol Number: NN6535-4730 Start Date*: 2021-04-29
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE)
    Medical condition: Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) CZ (Trial now transitioned) DE (Ongoing) FI (Trial now transitioned) IE (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) SI (Ongoing) DK (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) IT (Ongoing) FR (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004234-42 Sponsor Protocol Number: NN9535-4650 Start Date*: 2020-03-11
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of two different dose-escalation regimens for once-weekly semaglutide s.c. in subjects with type 2 diabetes mellitus previously treated with GLP-1 RAs
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000781-38 Sponsor Protocol Number: sempa1 Start Date*: 2019-05-07
    Sponsor Name:Aarhus University Hospital
    Full Title: Effect of Empagliflozin and Semaglutide on Cardio-Renal Target Organ Damage in patients with type 2 diabetes – A randomized Trial
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-001501-69 Sponsor Protocol Number: NN9535-4820 Start Date*: 2022-07-26
    Sponsor Name:Novo Nordisk A/S
    Full Title: Investigation of Clinical Comparability of Semaglutide Drug Products Based on the Proposed and the Approved Drug Substance Manufacturing Processes in Participants with Type 2 Diabetes
    Medical condition: Diabetes mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004864-25 Sponsor Protocol Number: NN6535-4725 Start Date*: 2021-04-29
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus)
    Medical condition: Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) CZ (Trial now transitioned) DE (Ongoing) FI (Trial now transitioned) IE (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) SI (Ongoing) DK (Ongoing) GR (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) IT (Ongoing) ES (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004994-16 Sponsor Protocol Number: NN9924-3790 Start Date*: 2013-10-23
    Sponsor Name:Novo Nordisk A/S
    Full Title: Multiple dose trial examining dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IT (Completed) DE (Completed) GB (Completed) BG (Completed) AT (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-000790-94 Sponsor Protocol Number: NN9536-4999 Start Date*: 2022-11-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity.
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing) NO (Ongoing) SK (Ongoing) HU (Ongoing) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003414-10 Sponsor Protocol Number: NN9536-4374 Start Date*: 2018-05-09
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity and type 2 diabetes
    Medical condition: 1. Obesity 2. Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    20.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2022-000404-35 Sponsor Protocol Number: 80519 Start Date*: 2022-07-26
    Sponsor Name:AMC, Cardiovascular Sciences
    Full Title: Does the hematopoietic stem cell govern residual inflammatory cardiovascular risk in type 2 diabetes?
    Medical condition: Inflammation in patients with type 2 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005435-75 Sponsor Protocol Number: U1111-1261-1912 Start Date*: 2022-07-21
    Sponsor Name:NOVO NORDISK. S.P.A.
    Full Title: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity
    Medical condition: Obesity, Overweight
    Disease: Version SOC Term Classification Code Term Level
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) NL (Ongoing) DK (Ongoing) FI (Ongoing) ES (Ongoing) PL (Ongoing) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002284-10 Sponsor Protocol Number: INS-4582 Start Date*: 2019-06-25
    Sponsor Name:Novo Nordisk A/S
    Full Title: A TRIAL TO COMPARE THE INJECTION SITE EXPERIENCE OF 0.25 MG SEMAGLUTIDE SC ADMINISTERED BY 2 DIFFERENT PRODUCTS
    Medical condition: Healthy volunteers (Diabetes Mellitus, Type 2) (Overweight) (Obesity)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    20.0 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA